학술논문
Neutralization capacity of highly divergent type 2 vaccine-derived polioviruses from immunodeficient patients.
Document Type
Academic Journal
Author
McDonald SL; IHRC, Inc. Atlanta, GA, Under Contract with Polio and Picornavirus Laboratory Branch, Centers for Disease Control and Prevention, USA.; Weldon WC; Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.; Wei L; IHRC, Inc. Atlanta, GA, Under Contract with Polio and Picornavirus Laboratory Branch, Centers for Disease Control and Prevention, USA.; Chen Q; Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.; Shaw J; Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.; Zhao K; Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.; Jorba J; Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.; Kew OM; Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.; Pallansch MA; Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.; Burns CC; Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.; Steven Oberste M; Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: mbo2@cdc.gov.
Source
Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE
Subject
Language
English
Abstract
The use of the oral poliovirus vaccine (OPV) in developing countries has reduced the incidence of poliomyelitis by >99% since 1988 and is the primary tool for global polio eradication. Spontaneous reversions of the vaccine virus to a neurovirulent form can impede this effort. In persons with primary B-cell immunodeficiencies, exposure to OPV can result in chronic infection, mutation, and excretion of immunodeficiency-associated vaccine-derived polioviruses, (iVDPVs). These iVDPVs may have the potential for transmission in a susceptible population and cause paralysis. The extent to which sera from OPV recipients are able to neutralize iVDPVs with varying degrees of antigenic site substitutions is investigated here. We tested sera from a population immunized with a combination vaccine schedule (both OPV and inactivated polio vaccine) against a panel of iVDPVs and found that increases in amino acid substitution in the P1 capsid protein resulted in a decrease in the neutralizing capacity of the sera. This study underscores the importance of maintaining high vaccine coverage in areas of OPV use as well as active surveillance of those known to be immunocompromised.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Published by Elsevier Ltd.)
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Published by Elsevier Ltd.)